GENESOFT®(EGF Eyedrop)

An EGF eye drop indicated for dry eye syndrome, corneal damage and post-operative healing

GeneSoft® is a colourless and transparent ophthalmic solution containing recombinant human epidermal growth factor (rEGF) for topical use which enhances the healing of cornea wounds by promoting corneal epithelium regeneration. GeneSoft® has a favourable competitive profile and, due to its stable formulation, can be stored at room temperature whilst other available wound healing products often require refrigeration and cold chain delivery.

GeneSoft® highlights:

In 2016, China Resources Zizhu is granted a 5-year sole distribution and promotion rights of Genesoft and will include the drug within its existing hospital network in Mainland China. Sales Partnership with CR Zizhu can potentially access 5 times the number of hospitals.

Protects the cornea and promotes its regeneration

Repairs the cornea and accelerates the restoration of cornea function after eye surgeries

Safe and widely applicable EGF for various ophthalmic wounds

Accelerates healing, shortening the healing time

Proven to be safe and effective without any side effects

Genesoft® is therapeutic drug for dry eye syndrome, corneal damage and post-operative healing, and has a competitive advantage of room temperature storage.

Genesoft® prevails over other ophthalmology products:

- Genesoft® has few competitors in the market, and has an convenient fill-finish to ensure ease of use for corneal wound healing patients

- Genesoft® targets epithelium such as the outermost layer of the cornea. EGF within Genesoft acts through EGF receptor on cell surface to enhance proliferation of keratinocyte and fibroblast to accelerate healing. It is worth to mention that Genesoft® is one of few drugs for healing acceleration while most drugs for post eye-surgery are anti-infective and steroids

- Genesoft® is stable under room temperature, allowing cheaper and easier transport and storage

- Genesoft® market is fast expanding, due to aging population in China and eye surgery becoming more common among elderly